Abstract
Androgen ablation is the choice of treatment for patients with advanced prostate cancer. Although untreated tumors are mostly androgen-dependent, hormone withdrawal is only palliative. The major problem in prostate cancer treatment represents the progression to androgen-independent growth during therapy, rendering current strategies inefficient. Thus, there is an urgent need to develop novel treatments to combat therapy-resistant prostate cancer. Intensive research strongly improved the knowledge about the molecular changes, which are believed to occur during prostate carcinogenesis and progression to androgen-independence. This in turn led to the identification of several interesting genes, which may be useful as targets for prostate cancer gene therapy. In fact, there is a broad range of different gene therapy approaches in the field of prostate cancer, some of which have already progressed to clinical evaluation in patients. Promising data and best benefit for patients currently provide studies where gene therapy strategies are combined with conventional treatments like chemotherapy or radiation. In this review we will give an overview of several interesting gene therapy concepts and delivery systems in prostate cancer and discuss their usefulness in the clinic.
Keywords: gene therapy, prostate cancer, antisense, viral vectors, ultrasound, microbubbles
Current Gene Therapy
Title: Gene Therapy Strategies in Prostate Cancer
Volume: 5 Issue: 1
Author(s): Iris E. Eder, Petra Haag, Georg Bartsch and Helmut Klocker
Affiliation:
Keywords: gene therapy, prostate cancer, antisense, viral vectors, ultrasound, microbubbles
Abstract: Androgen ablation is the choice of treatment for patients with advanced prostate cancer. Although untreated tumors are mostly androgen-dependent, hormone withdrawal is only palliative. The major problem in prostate cancer treatment represents the progression to androgen-independent growth during therapy, rendering current strategies inefficient. Thus, there is an urgent need to develop novel treatments to combat therapy-resistant prostate cancer. Intensive research strongly improved the knowledge about the molecular changes, which are believed to occur during prostate carcinogenesis and progression to androgen-independence. This in turn led to the identification of several interesting genes, which may be useful as targets for prostate cancer gene therapy. In fact, there is a broad range of different gene therapy approaches in the field of prostate cancer, some of which have already progressed to clinical evaluation in patients. Promising data and best benefit for patients currently provide studies where gene therapy strategies are combined with conventional treatments like chemotherapy or radiation. In this review we will give an overview of several interesting gene therapy concepts and delivery systems in prostate cancer and discuss their usefulness in the clinic.
Export Options
About this article
Cite this article as:
Eder E. Iris, Haag Petra, Bartsch Georg and Klocker Helmut, Gene Therapy Strategies in Prostate Cancer, Current Gene Therapy 2005; 5 (1) . https://dx.doi.org/10.2174/1566523052997424
DOI https://dx.doi.org/10.2174/1566523052997424 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research Glyceraldehyde-3-phosphate Dehydrogenase from Chironomidae Showed Differential Activity Towards Metals
Protein & Peptide Letters Understanding Prostate Cancer Cells Metabolome: A Spectroscopic Approach
Current Metabolomics Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?
Recent Patents on Anti-Cancer Drug Discovery Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Current Proteomics Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry ETS Proteins and MMPs: Partners in Invasion and Metastasis
Medicinal Chemistry Reviews - Online (Discontinued) Nutrient Regulation of Tumor and Vascular Endothelial Cell Proliferation
Current Cancer Drug Targets Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Current Signal Transduction Therapy Medications Affecting Functional Status in Older Persons
Current Pharmaceutical Design Genetic Association of CUGBP2 and DNMBP with Alzheimer’ s Disease in the Chinese Han Population
Current Alzheimer Research Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Scaling Down SAGE: from miniSAGE to microSAGE
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Ghrelin: A Gastric Peptide that Regulates Hypothalamic Control of Feeding
Current Medicinal Chemistry - Central Nervous System Agents Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Gold Nanoparticles as Carrier(s) for Drug Targeting and Imaging
Pharmaceutical Nanotechnology